

Variant: *NM_000314.8(PTEN):c.70G>A (p.Asp24Asn)*

Version: 1.0

CA000185 [↗](#)

185200 (ClinVar) [↗](#)

Gene: PTEN ([HGNC:5728](#))

Condition: PTEN hamartoma tumor syndrome ([MONDO:0017623](#))

Inheritance Mode: Autosomal dominant inheritance

UUID: d663419a-413e-4b9a-9410-9355060d6e3f

Approved on: 2026/6/16

Published on: 2026/6/26

HGVS expressions

NM_000314.8:c.70G>A

NM_000314.8(PTEN):c.70G>A (p.Asp24Asn)

NC_000010.11:g.87864539G>A

CM000672.2:g.87864539G>A

NC_000010.10:g.89624296G>A

CM000672.1:g.89624296G>A

NC_000010.9:g.89614276G>A

NG_007466.2:g.6101G>A

NG_033079.1:g.3899C>T

ENST00000700029.2:c.70G>A

ENST00000710265.1:c.70G>A

ENST00000472832.3:c.70G>A

ENST00000688922.2:c.70G>A

ENST00000700021.1:c.70G>A

ENST00000700022.1:c.70G>A

ENST00000706954.1:c.70G>A

ENST00000706955.1:c.70G>A

ENST00000686459.1:c.70G>A

ENST00000688158.1:c.70G>A

ENST00000688308.1:c.70G>A

ENST00000693560.1:c.589G>A

ENST00000371953.8:c.70G>A

ENST00000371953.7:c.70G>A

ENST00000462694.1:n.72G>A

ENST00000487939.1:n.91G>A

ENST00000610634.1:c.-33G>A

ENST00000618586.1:n.39G>A

NM_000314.5:c.70G>A

NM_000314.6:c.70G>A

NM_001304717.2:c.589G>A

NM_001304718.1:c.-636G>A

NM_000314.7:c.70G>A

NM_001304717.5:c.589G>A

NM_001304718.2:c.-636G>A

Pathogenic

Met criteria codes 5

PS3_Moderate

PP2

PP3

PM2_Supporting

PS2_Very Strong

Evidence Links 1

Expert Panel

PTEN VCEP

Criteria Specification Information

[Criteria Specification:](#) ClinGen PTEN Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for PTEN Version 3.2.0

[Criteria Specification Approval History](#)

[Criteria Specifications for this VCEP](#)

Evidence submitted by expert panel

PTEN VCEP

PTEN c.70G>A (p.Asp24Asn) meets criteria to be classified as Pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.2.0). Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column). PS2_VS: At least two proven OR one proven plus two assumed de novo observations in a patient with the disease and no family history. (internal laboratory contributors SCV001765320.4 and SCV005768039.2). PS3_M: Functional studies supportive of a damaging effect on the gene or gene product. Score of this variant = [-1.549791026] (≤ -1.11) on a high throughput phosphatase assay (PMID:29706350). PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. PP3: REVEL score > 0.7 (score of this variant = 0.753) PM2_P: Absent in large sequenced populations OR present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533).

Met criteria codes

PS3_Moderate			Functional studies supportive of a damaging effect on the gene or gene product. Score of this variant = [-1.549791026] (≤ -1.11) on a high throughput phosphatase assay (PMID:29706350).
			Functional studies supportive of a damaging effect on the gene or gene product. Score of this variant = [-1.549791026] (≤ -1.11) on a high throughput phosphatase assay (PMID:29706350). PubMed:29706350
PP2			PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.
PP3			REVEL score > 0.7 (score of this variant = 0.753)
PM2_Supporting			Absent in large sequenced populations OR present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533).
PS2_Very Strong			At least two proven OR one proven plus two assumed de novo observations in a patient with the disease and no family history. (internal laboratory contributors SCV001765320.4 and SCV005768039.2).



 ▾

 ▾

Showing 1 to 1 of 1 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.